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 In March 2006 a 57-year-old male was admitted to hos-
pital, complaining of a short period of asthenia and night 
sweats. Laboratory analysis demonstrated markedly ele-
vated leukocytes (37  ! 10 9 /l) with 87% of blasts, hemo-
globin of 10.4 g/dl and thrombocytopenia of 43  ! 10 9 /l. 
Subsequent bone marrow investigation revealed domi-
nant leukemic infiltration (90%) composed of myeloid 
blasts without maturation, consistent with the diagnosis 
of AML not otherwise categorized (according to WHO 
2008), morphologically type AML without maturation. 
Cytogenetics as well as molecular analysis remained un-
remarkable, giving no evidence of recurrent genetic ab-
normalities. The patient was treated on  HOVON 42 Pro-
tocol Arm A receiving 2 cycles of induction chemotherapy 
with cytarabine/idarubicin and cytarabine/amsacrine, 
respectively, which resulted in early first complete remis-
sion. According to the protocol and due to the lack of an 
appropriate donor for allogeneic hematopoietic stem cell 
transplantation, therapy was completed with consolida-
tion chemotherapy with mitoxantrone/etoposide. 
 Four years later, in June 2010, a slight thrombocytosis 
was first noted and increased in time to 717  ! 10 9 /l in 
June 2011, with otherwise normal full blood count values. 
Peripheral blood analysis for the JAK2 V617F mutation 
was positive (allele burden 34%). The red cell mass as well 
as the EPO level was in the normal range, and bone mar-
 Myeloproliferative neoplasms (MPN) are clonal stem 
cell disorders characterized by increased proliferation of 
one to three hematopoietic cell lineages. The protein ty-
rosine kinase JAK2 is mutated in virtually all patients 
with polycythemia vera and approximately 60% of pa-
tients with primary myelofibrosis or essential thrombo-
cythemia  [1] . In the past years less prevalent mutations 
involving MPL, TET2, ASXL1, CBL, IDH1 and IDH2, 
EZH2, DNMT3A as well as IKZF1 have additionally been 
described  [2] . The transformation of MPN in acute my-
eloid leukemia (AML) is a well-reported phenomenon. 
However, how JAK2 and other MPN-associated muta-
tions contribute to disease progression is still the subject 
of debate  [2–4] . In contrast, JAK2-positive MPN as sec-
ondary neoplasia occurring after AML is a rare clinical 
observation with only few case reports in the literature  [5, 
6] and little is known about the underlying pathophysiol-
ogy. Here we report the unique case of a 62-year-old pa-
tient with secondary MPN harboring JAK2 V617F, which 
presented with isolated thrombocytosis 4 years after suc-
cessful treatment with chemotherapy of a JAK2-negative 
AML. The idea that the expansion of the JAK2 V617F 
clone is associated with AML-linked factors is supported 
by the fact that our patient had a third malignancy, pan-
creatic cancer, associated with dysregulation in JAK/
STAT3 signaling. 
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row cytology and biopsy revealed signs of myeloprolifera-
tion without evidence of relapsing acute leukemia. The 
diagnosis of myeloproliferative neoplasia, most likely con-
sistent with essential thrombocythemia, was established 
according to WHO 2008 criteria  [7] . We retrospectively 
assessed JAK2 V617F mutational status in cryopreserved 
leukemic blasts and bone marrow biopsies at the diagnosis 
of AML and at remission time and all tests proved nega-
tive for the V617F mutant allele. Additional sequencing of 
genes frequently mutated in MPN or AML (MPL, TET2, 
ASXL1, CBL, IDH1 and IDH2, TP53, FLT3 and RUNX1) 
did not disclose any other somatic mutation, neither at 
AML diagnosis nor at MPN. The blood cell counts prior 
to AML diagnosis were unremarkable, excluding a preex-
isting, unrecognized, transformed MPN. 
 Cytoreductive treatment with hydroxyurea was initi-
ated and led to normalization of platelet count during 
follow-up. In February 2012, the patient presented with 
severe abdominal pain and was diagnosed as having pan-
creatic cancer with peritoneal carcinosis ( fig.  1 ). JAK2 
V617F mutation on extracted DNA from pancreatic tu-
mor cells turned out to be positive (allele burden 6%).
 The findings of our case report were considered conclu-
sive for the diagnosis of a secondary JAK2-positive MPN 
occurring after treatment of wild-type AML. The uncom-
mon sequence of the disease presentation raises a number 
of questions concerning the pathogenesis of both hemato-
logical diseases as well as the pancreatic tumor. It is sugges-
tive that the expansion of the JAK2 V617F clone is associ-
ated with AML-linked factors. It is possible that direct or 
indirect mechanisms led to JAK2 mutation through either 
predisposing factors in the initial AML clone or induced by 
chemotherapy. The idea of an AML-linked signaling alter-
ation is supported by the fact that our patient had a second 
malignancy, pancreatic cancer, which has been described 
in the literature to be associated with dysregulation of JAK/
STAT3 signaling  [8] . In contrast to a former study where 
STAT3 activation in pancreatic cancer was postulated to be 
driven by another mechanism than JAK2 V617F mutation 
 [9] the pancreatic tumor cells in our case turned out to har-
bor the JAK2 V617F mutation. However, in the case of a 
JAK2 V617F-positive disease-initiating pancreatic tumor 
cell, an allele burden of close to 100% would be expected. 
Considering the low allele burden of only 6% in our case, a 
contamination by intratumoral blood cells is very likely.
 On the other hand, both hematological diseases might 
be the expression of different phenotypes of the same 
clone, not fully eradicated by chemotherapy. Regarding 
our case, the lack of additional somatic mutations could 
neither support nor exclude this hypothesis. Further-
more, the idea of a favorable environment for the expan-
sion of a preexisting JAK2 V617F clone  [5] is not contra-
dictory to our case since the JAK2 V617F clone could have 
been below detection limit at AML diagnosis. Finally, the 
two hematological diseases could represent transforma-
tion of two completely independent stem cell clones. In 
agreement with the previously published case reports, the 
time interval of 4 to 5 years between chemotherapy and 
clinical evidence of MPN is similar.
 In conclusion, this unique case suggests an association 
between the initial AML and the following JAK2-positive 
secondary MPN as well as pancreatic cancer. Closer un-
derstanding of this complex phenomenon, especially the 
role of the AML clone itself and the effect of chemother-
apy on stem cell function and generation of JAK2 and 
other mutations, needs further investigation. 
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 Fig. 1. Sequence of disease and JAK2 V617F mutational status. BC = Blood count; CR = complete remission. 
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